SmithKline Beecham Paxil panic disorder and OCD claims approved by FDA.
SMITHKLINE BEECHAM PAXIL ELIMINATES FULL PANIC ATTACKS IN 76% of patients treated with Paxil 40 mg daily compared to 44% for placebo during a 10-week dose-ranging study, according to labeling for use of Paxil (paroxetine) in panic disorder. SmithKline Beecham's selective serotonin reuptake inhibitor was approved by FDA for the new indications of panic disorder and obsessive-compulsive disorder May 7. Paxil's supplemental NDA for panic disorder was submitted in March 1995. The supplemental NDA for OCD was filed in December 1994.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth